Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Boehringer Ingelheim Signs Option to Acquire US Biotech Trutino Biosciences.

Document Cited in Related
Vincent

MANews-(C)2009-2022

Germany-based pharmaceutical company Boehringer Ingelheim has signed an option to acquire San Diego, US-based biotech Trutino Biosciences Inc, the company said.

Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases.

Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers: through cancer cell-directed and immune cell-targeting compounds.

The ongoing research partnership between Boehringer Ingelheim and Trutino is part of an overarching effort to mobilize a patient's immune system to fight cancer.

Under the agreement, Boehringer Ingelheim reserves the right to purchase all shares of Trutino Biosciences once specified program milestones have been achieved within a given timeframe.

Until that time, Trutino will continue to operate as an independent company, with the existing fruitful strategic partnership and collaboration agreement between the companies continuing uninterrupted.

The transaction consideration consists of an option fee, the issuance...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT